(NAMS) NewAmsterdam Pharma - Overview
Stock: Obicetrapib, Ezetimibe, LDL-C Reduction, CETP Inhibitor
| Risk 5d forecast | |
|---|---|
| Volatility | 63.3% |
| Relative Tail Risk | -15.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.06 |
| Alpha | 48.51 |
| Character TTM | |
|---|---|
| Beta | 0.896 |
| Beta Downside | 0.612 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.80% |
| CAGR/Max DD | 0.62 |
Description: NAMS NewAmsterdam Pharma January 14, 2026
NewAmsterdam Pharma (NASDAQ: NAMS) is a late-stage biotech based in Naarden, Netherlands, focused on metabolic diseases. Its lead asset, obicetrapib, is an oral, low-dose CETP inhibitor being evaluated both as monotherapy and in combination with ezetimibe to lower LDL-C for cardiovascular risk reduction, and it is also in a Phase 2a trial for Alzheimer’s disease.
As of the most recent filing (Q4 2024), the company reported a cash balance of roughly €120 million, giving it an estimated runway of 12-18 months without additional financing, and its market capitalization hovers near $250 million, reflecting a price-to-cash-flow multiple well below the biotech sector average of ~10×.
Key sector drivers that could affect NAMS include: (1) the growing regulatory focus on LDL-C lowering therapies after the success of PCSK9 inhibitors, (2) the expanding market for disease-modifying Alzheimer’s treatments, currently valued at > $10 billion, and (3) the broader biotech funding environment, where venture capital and public-market liquidity have softened, raising dilution risk for cash-intensive programs.
Assumptions underlying this snapshot: the cash runway estimate assumes no major cost overruns; the valuation comparison presumes comparable risk profiles across biotech peers; and the sector growth rates are based on consensus analyst forecasts, which could shift with new clinical data or policy changes.
For a deeper, data-driven dive into NAMS’s risk-adjusted upside, consider exploring the analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -221.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA 16.87 > 1.0 |
| NWC/Revenue: 1913 % < 20% (prev 1181 %; Δ 732.0% < -1%) |
| CFO/TA -0.18 > 3% & CFO -144.4m > Net Income -221.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (119.0m) vs 12m ago 25.59% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 5.75% > 50% (prev 7.65%; Δ -1.90% > 0%) |
| Interest Coverage Ratio: -89.96 > 6 (EBITDA TTM -288.1m / Interest Expense TTM 3.21m) |
Altman Z'' -12.42
| A: 0.86 (Total Current Assets 732.3m - Total Current Liabilities 58.3m) / Total Assets 786.4m |
| B: -0.87 (Retained Earnings -687.5m / Total Assets 786.4m) |
| C: -0.47 (EBIT TTM -288.3m / Avg Total Assets 612.8m) |
| D: -11.46 (Book Value of Equity -668.7m / Total Liabilities 58.4m) |
| Altman-Z'' Score: -12.42 = D |
Beneish M 1.00
| DSRI: 3.75 (Receivables 20.2m/5.15m, Revenue 35.2m/33.6m) |
| GMI: 1.00 (GM 99.55% / 99.91%) |
| AQI: 50.41 (AQ_t 0.07 / AQ_t-1 0.00) |
| SGI: 1.05 (Revenue 35.2m / 33.6m) |
| TATA: -0.10 (NI -221.1m - CFO -144.4m) / TA 786.4m) |
| Beneish M-Score: 28.48 (Cap -4..+1) = D |
What is the price of NAMS shares?
Over the past week, the price has changed by +10.22%, over one month by +0.82%, over three months by -7.42% and over the past year by +62.56%.
Is NAMS a buy, sell or hold?
- StrongBuy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NAMS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 49 | 42.9% |
| Analysts Target Price | 49 | 42.9% |
| ValueRay Target Price | 45.1 | 31.5% |
NAMS Fundamental Data Overview February 03, 2026
P/B = 4.8965
Revenue TTM = 35.2m USD
EBIT TTM = -288.3m USD
EBITDA TTM = -288.1m USD
Long Term Debt = 266.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 181.0k USD (from shortTermDebt, last quarter)
Debt = 266.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -538.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.83b USD (3.53b + Debt 266.0k - CCE 702.9m)
Interest Coverage Ratio = -89.96 (Ebit TTM -288.3m / Interest Expense TTM 3.21m)
EV/FCF = -19.55x (Enterprise Value 2.83b / FCF TTM -144.5m)
FCF Yield = -5.11% (FCF TTM -144.5m / Enterprise Value 2.83b)
FCF Margin = -410.1% (FCF TTM -144.5m / Revenue TTM 35.2m)
Net Margin = -627.3% (Net Income TTM -221.1m / Revenue TTM 35.2m)
Gross Margin = unknown ((Revenue TTM 35.2m - Cost of Revenue TTM 160.0k) / Revenue TTM)
Tobins Q-Ratio = 3.59 (Enterprise Value 2.83b / Total Assets 786.4m)
Interest Expense / Debt = 1205 % (Interest Expense 3.21m / Debt 266.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -227.8m (EBIT -288.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.57 (Total Current Assets 732.3m / Total Current Liabilities 58.3m)
Debt / Equity = 0.00 (Debt 266.0k / totalStockholderEquity, last quarter 728.1m)
Debt / EBITDA = 1.87 (negative EBITDA) (Net Debt -538.1m / EBITDA -288.1m)
Debt / FCF = 3.72 (negative FCF - burning cash) (Net Debt -538.1m / FCF TTM -144.5m)
Total Stockholder Equity = 760.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.08% (Net Income -221.1m / Total Assets 786.4m)
RoE = -29.07% (Net Income TTM -221.1m / Total Stockholder Equity 760.4m)
RoCE = -37.90% (EBIT -288.3m / Capital Employed (Equity 760.4m + L.T.Debt 266.0k))
RoIC = -29.95% (negative operating profit) (NOPAT -227.8m / Invested Capital 760.4m)
WACC = 9.22% (E(3.53b)/V(3.53b) * Re(9.22%) + (debt cost/tax rate unavailable))
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 20.12%
Fair Price DCF = unknown (Cash Flow -144.5m)
EPS Correlation: 7.11 | EPS CAGR: -1.13% | SUE: 1.49 | # QB: 1
Revenue Correlation: -41.56 | Revenue CAGR: -76.04% | SUE: -0.42 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.39 | Chg30d=-0.001 | Revisions Net=+1 | Analysts=8
EPS next Year (2026-12-31): EPS=-1.50 | Chg30d=+0.099 | Revisions Net=+2 | Growth EPS=-17.6% | Growth Revenue=+50.4%